Roca Cusachs, AlexAracil vilar, JoaquínCalvo Gómez, CarlosVaquer Pérez, José VicenteLaporta Crespo, FélixRojas Serrano, María JoséGuglietta, AntonioGropper, SavionSobrino, Javier2020-02-212020-02-2120081755-5914https://hdl.handle.net/2445/150971The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double‐blind trial. Patients with newly diagnosed mild‐to‐moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide‐PR (n = 219) or torasemide‐IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide‐PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide‐IR (11.3 ± 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide‐PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24‐h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide‐PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar.10 p.application/pdfengcc-by (c) Roca Cusachs, Alex et al., 2008http://creativecommons.org/licenses/by/3.0/esMedicaments d'alliberament retardatPressió sanguíniaDelayed-action drugsBlood pressureinfo:eu-repo/semantics/article6021702020-02-21info:eu-repo/semantics/openAccess